Concerns Halt Idenix Hep C Drug
Idenix: FDA Places Hepatitis C Treatment on Clinical Hold
Published August 27, 2012
Dow Jones Newswires
Idenix Pharmaceuticals Inc. (IDIX) said the Food and Drug Administration placed a clinical hold on one of its treatments for hepatitis C, the latest setback for the drug developer.
The clinical hold on the treatment–IDX19368–is related to the regulator’s heart-safety concerns about rival Bristol-Myers Squibb Co.’s (BMY) closely watched treatment for the liver disease, which belongs to the same class of drugs–known as nucleotide polymerase inhibitors.
Continue reading this entire article:
Drug-Related Fatality Stops Hepatitis C Trial
Hepatitis C Biopump Trials Get Green Light